<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003434</url>
  </required_header>
  <id_info>
    <org_study_id>1259</org_study_id>
    <secondary_id>DUMC-97093</secondary_id>
    <secondary_id>NCI-G98-1457</secondary_id>
    <secondary_id>CDR0000066460</secondary_id>
    <nct_id>NCT00003434</nct_id>
  </id_info>
  <brief_title>Biological Therapy in Stage I, Stage II, or Stage III Surgically Resected Pancreatic Cancer</brief_title>
  <official_title>A Pilot Study of Active Immunotherapy With Carcinoembryonic Antigen Peptide-Pulsed, Autologous Human Cultured Dendritic Cells in Patients With Resected, Stage I, II and III Pancreatic Adenocarcinoma Expressing Carcinoembryonic Antigen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rational: White blood cells that have been treated with carcinoembryonic antigen peptide-1&#xD;
      may help the body build an immune response to and kill tumor cells that express CEA.&#xD;
&#xD;
      Purpose: Phase II trial to study the effectiveness of white blood cells plus carcinoembryonic&#xD;
      antigen peptide-1 in treating patients with stage I, stage II, or stage III pancreatic cancer&#xD;
      that has been surgically removed.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objective: I. Perform a pilot study of active immunotherapy with autologous dendritic cells&#xD;
      pulsed with the CEA peptide, CAP-1, after surgical resection in patients with CEA expressing&#xD;
      pancreatic cancer. II. Perform laboratory analysis to monitor the presence, persistence, and&#xD;
      function of CAP-1 specific T-cells in this patient population.&#xD;
&#xD;
      Outline: Patients undergo leukapheresis for up to 4.5 hours prior to vaccination. Half of the&#xD;
      collected dendritic cells are pulsed with carcinoembryonic antigen (CEA) peptide and the&#xD;
      other half are pulsed with hepatitis B antigen peptide (HBsAg). Equal doses of CEA and HBsAg&#xD;
      peptide pulsed dendritic cells are administered intravenously over 3 minutes every 4 weeks&#xD;
      for a total of 6 doses each. Patients undergo a second leukopheresis 2 weeks after the last&#xD;
      dose of immunotherapy to obtain specimens for immunologic tests. Patients are followed at&#xD;
      weeks 22, 36, 48, and every 6 months thereafter.&#xD;
&#xD;
      Project Accrual: A total of 24 patients will be accrued for this study over 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>June 1998</start_date>
  <completion_date type="Actual">August 2002</completion_date>
  <primary_completion_date type="Actual">August 2002</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival</measure>
  </primary_outcome>
  <enrollment type="Actual">8</enrollment>
  <condition>Pancreatic Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>carcinoembryonic antigen peptide 1</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>hepatitis B antigen peptide</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Disease Characteristics:&#xD;
&#xD;
          -  Histologically confirmed stage I, II, or III adenocarcinoma of the pancreas Resected&#xD;
             with no gross residual disease At least 50% of tumor cells must be CEA positive and&#xD;
             stain with at least moderate intensity HLA-A2 positive&#xD;
&#xD;
        Patient Characteristics:&#xD;
&#xD;
          -  Age: 18 and over&#xD;
&#xD;
          -  Performance status: Karnofsky 70-100%&#xD;
&#xD;
          -  Life expectancy: Greater than 6 months&#xD;
&#xD;
          -  Hematopoietic: Absolute neutrophil count at least 1000/mm3&#xD;
&#xD;
          -  Hepatic: Bilirubin less than 2.0 mg/dL SGOT and alkaline phosphatase less than 4 times&#xD;
             the upper limit of normal No hepatic failure&#xD;
&#xD;
          -  Renal: Creatinine less than 2.0 mg/dL OR Creatinine clearance greater than 50 mL/min&#xD;
&#xD;
          -  Cardiovascular: No New York Heart Association class III or IV heart disease&#xD;
&#xD;
          -  Pulmonary: No concurrent asthma or chronic obstructive pulmonary disease&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No other malignancy except nonmelanoma skin cancer or controlled superficial bladder&#xD;
             cancer within the past 5 years.&#xD;
&#xD;
          -  No history of autoimmune diseases such as inflammatory bowel disease, systemic lupus&#xD;
             erythematosus, ankylosing spondylitis, scleroderma, rheumatoid arthritis, or multiple&#xD;
             sclerosis&#xD;
&#xD;
          -  No active acute or chronic infection such as urinary tract infection, HIV, or viral&#xD;
             hepatitis&#xD;
&#xD;
          -  No active infectious enteritis or eosinophilic enteritis Not pregnant or nursing&#xD;
             Fertile patients must use effective contraception&#xD;
&#xD;
        Prior Therapy:&#xD;
&#xD;
          -  Biologic therapy: At least 4 weeks since immunotherapy. No other concurrent&#xD;
             immunotherapy&#xD;
&#xD;
          -  Chemotherapy: At least 4 weeks since chemotherapy and recovered. No concurrent&#xD;
             chemotherapy&#xD;
&#xD;
          -  Endocrine therapy: No concurrent corticosteroid or immunosuppressive therapy. At least&#xD;
             6 weeks since steroid therapy&#xD;
&#xD;
          -  Radiotherapy: At least 4 weeks since radiotherapy and recovered&#xD;
&#xD;
          -  Surgery: Recovered from prior surgery&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael A. Morse, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke Comprehensive Cancer Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>April 26, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 27, 2004</study_first_posted>
  <last_update_submitted>February 7, 2014</last_update_submitted>
  <last_update_submitted_qc>February 7, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 10, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage I pancreatic cancer</keyword>
  <keyword>stage II pancreatic cancer</keyword>
  <keyword>stage III pancreatic cancer</keyword>
  <keyword>adenocarcinoma of the pancreas</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

